<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819934</url>
  </required_header>
  <id_info>
    <org_study_id>KD101_hAME</org_study_id>
    <nct_id>NCT02819934</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Investigate the ADME of KD101</brief_title>
  <official_title>A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of KD101 in Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of KD101 in Male&#xD;
      Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of KD101 in Male&#xD;
      Subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2016</start_date>
  <completion_date type="Actual">December 15, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity at feces,urine,blood to measure total recovery rate</measure>
    <time_frame>13day</time_frame>
    <description>radioactivity in nCi</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimental group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD101</intervention_name>
    <description>after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral</description>
    <arm_group_label>Arm1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are able to provide written informed consent&#xD;
&#xD;
          -  The subject is a healthy Korean aged 20 to 55 years, inclusive.&#xD;
&#xD;
          -  The subject weighs at least 55 and has a body mass index (BMI)over 27&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with evidence or a history of clinically significant pulmonary,&#xD;
             cardiovascular, hepatic, endocrine, hematological, neurologic or psychiatric diseases.&#xD;
&#xD;
          -  Subjects with evidence of gastrointestinal disease which can affect the absorption of&#xD;
             drug.&#xD;
&#xD;
          -  Subjects with a history of drug abuse or a positive result in the urine drug screening&#xD;
             for drug abuse&#xD;
&#xD;
          -  Subjects who have taken any prescribed medicine or herbal medicine within 2 weeks&#xD;
             before the first administration of the investigational product, any non-prescribed&#xD;
             medicine or vitamin supplement within 1 week prior the first administration of the&#xD;
             investigational product (if all other conditions are satisfied, subjects may be&#xD;
             eligible for the trial as judged by the investigator.)&#xD;
&#xD;
          -  Subjects who have donated a unit of whole blood within 30 days or who have&#xD;
             participated in any other clinical trial within 60 days prior the first administration&#xD;
             of the investigational product&#xD;
&#xD;
          -  Subject who have history of allergy.&#xD;
&#xD;
          -  Subject who can not continue proper contraception method during study period.&#xD;
&#xD;
          -  Subjects who consume more than 21 units of alcohol per week (1 unit = 10 g of pure&#xD;
             alcohol) or who are unable to abstain from drinking during the PK/PD testing period&#xD;
&#xD;
          -  Subjects who are unable to abstain from smoking during the PK/PD testing period&#xD;
&#xD;
          -  Subjects who are unable to abstain from grapefruit or caffeine containing food 1 day&#xD;
             prior the first administration of the investigational product&#xD;
&#xD;
          -  Subjects judged not eligible for the study after reviewing the clinical laboratory&#xD;
             results or other reasons by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 30, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Howard Lee</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

